A recent study in the United States has revealed that anti-obesity injections like semaglutide and tirzepatide may not be as effective in real-world settings as they appear in clinical trials. The research found that many patients discontinued treatment or reduced their dosages, leading to less significant weight loss and poorer glycemic control. According to Dr. Hamlet Gasoyan from the Cleveland Clinic, the study, published in the *Obesity Journal*, followed 7,881 adults and highlighted several reasons for the treatment discontinuation. These included issues with insurance coverage, side effects, and medication shortages, all of which significantly impacted the effectiveness of the medications.
The study’s findings suggest that while these injections have proven effective in clinical trials for managing weight and controlling blood sugar levels, they may not produce the same results in everyday use. The high rate of discontinuation and changes in dosage regimens were key factors that led to the reduced effectiveness.
The research also pointed out that patients with pre-diabetes, in particular, experienced less control over their blood sugar due to these challenges. While the medications are primarily used for weight management and type 2 diabetes treatment, the real-world barriers to consistent use may limit their overall impact.
This study underscores the importance of understanding the differences between controlled clinical trial environments and the challenges faced by patients in everyday life. As the use of such medications continues to grow, especially with the increasing demand for anti-obesity treatments, addressing these real-world issues may be crucial for improving their effectiveness.
Related Topics:
UAE Doctors Warn Against Off-Label Ozempic Mounjaro Use
New Weight-Loss Drugs Less Effective in Real Life Than Trials
